Shigella flexneri in Uttar Pradesh, India: Epidemiology, Clinical Manifestations, Antimicrobial Resistance, and Public Health Implications from January 2025 to January 2026
1. Ritik Kumar
2. Satybaldyev Mederbek
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Lecturer, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Shigella flexneri remains a formidable cause of bacillary dysentery across the Indian subcontinent, disproportionately affecting children in settings with inadequate water, sanitation, and hygiene infrastructure. This review examines the epidemiological landscape, clinical characteristics, antimicrobial resistance patterns, and public health implications of Shigella flexneri infection in Uttar Pradesh, India's most populous state, during the period from January 2025 to January 2026. A comprehensive literature search was conducted focusing on publications from 2017 to 2025, with particular emphasis on recent surveillance data from northern India and the evolving antimicrobial resistance crisis. The analysis reveals that Shigella flexneri continues to predominate among Shigella species isolated in India, with serotype 2a being the most prevalent, though shifting trends toward S. sonnei are emerging in certain regions. Antimicrobial resistance has reached alarming proportions, with multidrug resistance rates exceeding 90% in many settings and increasing resistance to fluoroquinolones, third-generation cephalosporins, and azithromycin threatening to exhaust available treatment options. The disease burden falls heaviest upon children under five years of age, with complications including hemolytic uremic syndrome, reactive arthritis, and growth faltering carrying substantial long-term consequences. Strengthening laboratory surveillance, implementing antimicrobial stewardship programs, accelerating vaccine development, and investing in water and sanitation infrastructure are essential to controlling this persistent public health threat.
Introduction
The ancient scourge of dysentery, characterized by bloody diarrhea accompanied by fever, abdominal cramping, and tenesmus, continues to afflict millions of children across the developing world despite decades of medical progress. Among the pathogens responsible for this clinical syndrome, Shigella flexneri occupies a position of particular significance in South Asia, where it has long reigned as the predominant cause of bacillary dysentery. In Uttar Pradesh, India's most populous state with over 240 million inhabitants, the burden of shigellosis remains substantial yet incompletely quantified, hidden within the broader category of diarrheal diseases that continue to claim young lives despite being largely preventable and treatable.
Shigella flexneri, a gram-negative, non-motile, facultatively anaerobic bacillus belonging to the family Enterobacteriaceae, possesses a remarkable capacity for human-to-human transmission through the fecal-oral route. The infectious dose is extraordinarily low—as few as ten to one hundred organisms suffice to establish infection—rendering the bacterium exceptionally contagious and capable of explosive spread in crowded settings with poor hygiene. The organism's resilience in the environment, its ability to survive in contaminated water and food, and its propensity for causing secondary cases among household contacts create conditions for sustained transmission in communities lacking safe water and adequate sanitation.
The clinical syndrome produced by S. flexneri infection ranges from mild watery diarrhea to severe dysentery with intestinal and extraintestinal complications. Children under five years of age bear the brunt of disease severity, experiencing higher rates of complications including seizures, hemolytic uremic syndrome, reactive arthritis, and growth faltering. The long-term consequences of repeated shigellosis episodes extend beyond acute morbidity, contributing to malnutrition, impaired cognitive development, and diminished educational attainment—outcomes that perpetuate cycles of poverty and vulnerability.
The therapeutic landscape for shigellosis has darkened considerably with the emergence and dissemination of antimicrobial resistance. Once susceptible to inexpensive, widely available agents including ampicillin, trimethoprim-sulfamethoxazole, and tetracycline, contemporary S. flexneri isolates from India demonstrate multidrug resistance rates exceeding 90% in many surveillance studies. The subsequent reliance on fluoroquinolones and third-generation cephalosporins has been undermined by rising resistance to these agents as well, leaving clinicians with increasingly limited options for empirical therapy. The recent emergence of extensively drug-resistant strains resistant to all recommended first-line and second-line agents represents a crisis demanding urgent attention.
Uttar Pradesh presents a microcosm of the challenges confronting shigellosis control in India. The state's vast population, uneven health infrastructure, significant rural-urban disparities, and periodic flooding during monsoon seasons create conditions conducive to sustained transmission. Understanding the epidemiology, clinical manifestations, and resistance patterns of S. flexneri in this setting is essential for informing evidence-based interventions and allocating resources effectively. This review examines the current state of knowledge regarding S. flexneri infection in Uttar Pradesh during the period from January 2025 to January 2026, synthesizing available surveillance data, clinical studies, and public health reports to provide a comprehensive assessment of this persistent threat.
Methods
A comprehensive literature search was conducted to identify relevant publications addressing Shigella flexneri epidemiology, clinical characteristics, antimicrobial resistance, and public health implications in Uttar Pradesh and northern India. The search encompassed databases including PubMed, MEDLINE, and the Cochrane Library, with primary focus on literature published between January 2017 and October 2025 to ensure inclusion of contemporary surveillance data and emerging resistance trends. Search terms incorporated "Shigella flexneri," "shigellosis," "Uttar Pradesh," "India," "antimicrobial resistance," "bacillary dysentery," "children," "diarrhea," and "surveillance."
Inclusion criteria prioritized original research articles, surveillance reports, outbreak investigations, and clinical studies specifically addressing Uttar Pradesh or northern Indian populations, or containing substantial data relevant to these regions. The methodological framework emphasized evidence from the Indian Council of Medical Research surveillance networks, National Centre for Disease Control reports, and peer-reviewed publications from major medical institutions in Uttar Pradesh including King George's Medical University, Banaras Hindu University, and Aligarh Muslim University. Particular attention was directed toward studies characterizing antimicrobial susceptibility patterns, serotype distribution, clinical outcomes, and molecular epidemiology of S. flexneri isolates.
The analysis synthesized data from multiple study designs, acknowledging the inherent limitations of shigellosis surveillance in India including underreporting, selection bias toward severe cases presenting to tertiary care centers, and incomplete geographical coverage. Reference was made to key epidemiological studies including the Global Enteric Multicenter Study (GEMS), the Vaccine Impact on Diarrhea in Africa and Asia (VIDA) study, and regional surveillance reports from the Indian Council of Medical Research. Where Uttar Pradesh-specific data were unavailable, findings from comparable settings in northern India were extrapolated with appropriate caveats regarding generalizability.
Results
Epidemiology and Disease Burden
Shigella flexneri maintains its position as the predominant cause of bacillary dysentery across India, though the epidemiological landscape is evolving. Nationwide surveillance data indicate that S. flexneri accounts for approximately 60-80% of Shigella isolates from diarrheal patients, with serotype 2a being the most commonly identified followed by serotypes 3a, 6, and 1b. However, a notable shift is occurring in certain regions, with S. sonnei demonstrating increasing prevalence in urban and peri-urban settings—a pattern previously observed in industrialized countries and now emerging in India as economic development and sanitation infrastructure improve in select areas.
In Uttar Pradesh specifically, the burden of shigellosis remains substantial though incompletely quantified. The state's Integrated Disease Surveillance Programme captures reported cases of acute diarrheal disease, but laboratory confirmation of Shigella infection is limited by inadequate diagnostic capacity at primary and secondary health facilities. Tertiary care centers in major cities including Lucknow, Varanasi, Kanpur, and Agra report consistent isolation of S. flexneri from pediatric diarrheal admissions, with seasonal peaks corresponding to the monsoon period from July through September. The flooding that accompanies heavy monsoon rains contaminates drinking water sources and disrupts sanitation systems, creating conditions for explosive transmission.
The age distribution of shigellosis in Uttar Pradesh mirrors patterns observed across South Asia, with the highest incidence among children under five years of age. This vulnerable population experiences more severe disease, higher complication rates, and greater mortality risk. Breastfeeding appears to confer partial protection, with non-breastfed infants demonstrating increased susceptibility to severe disease. Malnourished children face compounded risks, with shigellosis and malnutrition forming a vicious cycle wherein each condition exacerbates the other.
Transmission dynamics in Uttar Pradesh reflect the fecal-oral route predominant in settings with inadequate sanitation. Person-to-person transmission within households and communities accounts for the majority of cases, with contaminated water and food serving as vehicles for larger outbreaks. The low infectious dose of Shigella—requiring as few as ten to one hundred organisms—facilitates efficient secondary transmission, with attack rates among household contacts approaching 40% in some studies. Asymptomatic carriers, particularly children, contribute to sustained community transmission.
Clinical Manifestations
The clinical presentation of S. flexneri infection in Uttar Pradesh encompasses a spectrum from mild watery diarrhea to severe dysentery with systemic complications. The incubation period typically ranges from 12 hours to 3 days following ingestion. Initial symptoms often include fever, abdominal cramping, and anorexia, progressing to diarrhea that may initially be watery before evolving into the characteristic dysentery with frequent, small-volume stools containing blood, mucus, and inflammatory cells.
In the VIDA study, which included sites in South Asia, Shigella-associated dysentery was more common in children aged 24-59 months (50.1%) compared with infants younger than 11 months (39.5%), with S. flexneri infection producing dysentery in 60.3% of cases compared to 44.4% for S. sonnei. This predilection for causing bloody diarrhea reflects the organism's capacity for epithelial invasion and induction of intense mucosal inflammation.
Severe disease manifestations include high fever exceeding 40°C, toxic appearance, and frequent stools numbering twenty or more per day. Young children, particularly those under two years of age, may develop febrile seizures, with convulsions reported in up to 25% of Shigella infections involving children under four years in some series. The pathophysiology of these seizures appears multifactorial, involving high fever, electrolyte disturbances, and possibly direct neurotoxic effects of bacterial products.
Intestinal complications, while less common than in S. dysenteriae type 1 infection, include rectal prolapse, toxic megacolon, and intestinal perforation. Rectal prolapse occurs primarily in young children with severe tenesmus and frequent straining. Toxic megacolon represents a surgical emergency requiring prompt recognition and intervention. Intestinal perforation, though rare, carries high mortality when it occurs.
Extraintestinal complications of S. flexneri infection deserve particular attention given their potential for long-term morbidity. Bacteremia occurs primarily in malnourished infants and immunocompromised patients, carrying mortality rates exceeding 20% in some series. Hemolytic uremic syndrome, while classically associated with S. dysenteriae type 1, has been reported following S. flexneri infection, typically developing 7-10 days after onset of dysentery as the intestinal symptoms are resolving. This complication, characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, carries mortality rates of 15-36% and may result in chronic renal dysfunction among survivors.
Reactive arthritis represents another important post-infectious manifestation, occurring in approximately 1-2% of infected individuals, particularly those harboring the HLA-B27 haplotype. This seronegative spondyloarthropathy typically develops 1-4 weeks after infection, manifesting as asymmetric oligoarthritis, enthesitis, and dactylitis, often accompanied by extra-articular features including conjunctivitis and urethritis. While symptoms generally resolve within 6-12 months, chronic arthritis may persist in some patients.
The long-term consequences of shigellosis extend beyond recognized complications to include growth faltering and impaired cognitive development. Repeated episodes of shigellosis contribute to environmental enteric dysfunction, a condition of chronic intestinal inflammation and malabsorption that stunts linear growth and impairs neurodevelopment. These sequelae, often invisible in acute disease statistics, represent a substantial hidden burden of shigellosis in Uttar Pradesh and similar settings.
Antimicrobial Resistance
The antimicrobial resistance landscape of S. flexneri in India presents a crisis of escalating severity. Historical surveillance from northern India documented the progressive loss of susceptibility to first-line agents, with resistance to ampicillin, trimethoprim-sulfamethoxazole, and tetracycline now exceeding 80% in many settings. This multidrug resistance, defined as resistance to two or more antimicrobial classes, has become the norm rather than the exception.
Fluoroquinolone resistance has emerged as a particular concern. Ciprofloxacin, once the mainstay of empirical therapy for shigellosis, now demonstrates resistance rates exceeding 50% in many Indian surveillance studies. The mechanisms underlying fluoroquinolone resistance involve chromosomal mutations in the quinolone resistance-determining regions of gyrA and parC genes, encoding DNA gyrase and topoisomerase IV respectively. Common mutations include substitutions at serine 83 and aspartic acid 87 of gyrA and serine 80 of parC. Plasmid-mediated quinolone resistance genes, including qnr variants and aac(6')-Ib-cr, contribute additional resistance mechanisms and facilitate horizontal dissemination.
Third-generation cephalosporin resistance, mediated primarily by extended-spectrum beta-lactamases including CTX-M-15, TEM, and OXA variants, has risen alarmingly. Studies from northern India report ceftriaxone resistance rates approaching 20% among S. flexneri isolates, with some centers documenting even higher prevalence. The production of AmpC beta-lactamases, including CMY-2, adds to the complexity of resistance mechanisms. These enzymes hydrolyze cephalosporins and are not inhibited by clavulanic acid, rendering amoxicillin-clavulanate ineffective.
Azithromycin, recommended by the World Health Organization as an alternative agent for shigellosis, has demonstrated decreasing susceptibility in recent years. Decreased susceptibility to azithromycin, defined by elevated minimum inhibitory concentrations without meeting formal resistance breakpoints, has been reported in 35% or more of isolates from some Indian centers. The mphA gene, encoding a macrolide phosphotransferase, has been identified as a key resistance determinant.
The convergence of these resistance mechanisms has produced extensively drug-resistant S. flexneri strains resistant to all recommended first-line and second-line agents. Recent reports from South Asia and elsewhere document strains resistant to ampicillin, trimethoprim-sulfamethoxazole, ciprofloxacin, ceftriaxone, and azithromycin—leaving clinicians with essentially no reliable options for oral empirical therapy. The emergence of such strains in Uttar Pradesh, whether through local evolution or importation from other regions, would represent a public health emergency requiring immediate response.
The drivers of antimicrobial resistance in S. flexneri are multifactorial. The ubiquitous availability of antibiotics without prescription, widespread use in veterinary medicine, inadequate dosing and duration of therapy when antibiotics are appropriately indicated, and poor infection control practices in healthcare facilities all contribute to selective pressure favoring resistant strains. The horizontal transfer of resistance genes via plasmids, integrons, and transposons facilitates rapid dissemination of resistance determinants among Shigella strains and across species boundaries.
Diagnosis
The diagnosis of shigellosis in Uttar Pradesh relies heavily on clinical suspicion, with laboratory confirmation available primarily at tertiary care centers and reference laboratories. The characteristic presentation of acute dysentery—frequent, small-volume stools containing blood and mucus accompanied by fever and tenesmus—should prompt consideration of shigellosis, particularly in children during the monsoon season. However, the clinical syndrome cannot be reliably distinguished from other causes of inflammatory diarrhea including enteroaggregative Escherichia coli, Campylobacter jejuni, and Entamoeba histolytica without laboratory testing.
Stool microscopy demonstrating abundant leukocytes and erythrocytes supports the diagnosis of inflammatory diarrhea but lacks specificity for Shigella. Stool culture remains the gold standard for diagnosis, with isolation of S. flexneri on selective media including MacConkey agar, xylose lysine deoxycholate agar, and Hektoen enteric agar. Presumptive identification based on biochemical reactions is confirmed by serological agglutination with specific antisera. The sensitivity of stool culture is compromised by delayed specimen transport, prior antibiotic administration, and the fastidious nature of Shigella, which may fail to grow if specimens are not promptly processed.
Antimicrobial susceptibility testing of confirmed isolates is essential for guiding therapy and surveillance. The disk diffusion method following Clinical and Laboratory Standards Institute guidelines is most commonly employed, with minimum inhibitory concentration determination by broth microdilution or E-test providing more precise quantification for surveillance purposes. Molecular methods including polymerase chain reaction for resistance genes and whole genome sequencing for outbreak investigation and resistance mechanism characterization are available at reference centers but not routinely accessible.
Rapid diagnostic tests for shigellosis, including immunochromatographic assays detecting Shigella antigens and molecular assays targeting species-specific genes, are under development and evaluation. These tests could potentially enable point-of-care diagnosis and guide appropriate antibiotic use, but none are currently widely available in Uttar Pradesh. The development and deployment of affordable, accurate rapid diagnostics represent a research priority for improving shigellosis management in resource-limited settings.
Treatment
The management of S. flexneri infection in Uttar Pradesh must navigate the tension between the imperative to treat severe disease promptly and the reality of escalating antimicrobial resistance. Supportive care forms the foundation of management for all patients, with particular attention to hydration status and electrolyte balance. Oral rehydration solution should be administered to patients with mild to moderate dehydration, while intravenous fluids are reserved for those with severe dehydration, shock, or inability to tolerate oral intake. Zinc supplementation, recommended by the World Health Organization for children under five years with diarrhea, reduces the duration and severity of episodes and should be routinely provided.
Antibiotic therapy is indicated for patients with severe disease, dysentery, immunocompromise, malnutrition, or suspected sepsis. The choice of empirical antibiotic must be guided by local susceptibility patterns, which in Uttar Pradesh increasingly favor agents with reliable activity against resistant strains. The World Health Organization recommends ciprofloxacin as first-line therapy where susceptibility is documented, with pivmecillinam, ceftriaxone, or azithromycin as alternatives. However, the high prevalence of fluoroquinolone resistance in many Indian settings necessitates caution in relying on ciprofloxacin for empirical therapy.
Ceftriaxone, administered parenterally, remains effective against many contemporary S. flexneri isolates and is appropriate for hospitalized patients with severe disease. However, the emergence of extended-spectrum beta-lactamase-producing strains threatens even this option. Azithromycin offers the advantage of oral administration and intracellular penetration, but decreasing susceptibility requires monitoring. The optimal duration of antibiotic therapy for shigellosis is typically 3-5 days for uncomplicated cases, though longer courses may be necessary for severe disease or immunocompromised patients.
The role of antimicrobial stewardship in preserving effective therapy cannot be overstated. Antibiotics should be reserved for patients who will benefit—those with severe disease or risk factors for complications—rather than administered to all patients with diarrhea. The inappropriate use of antibiotics for viral diarrhea or mild self-limiting illness drives resistance without benefiting patients. Education of healthcare providers and the public regarding appropriate antibiotic use is essential.
The development of effective vaccines against Shigella represents the most promising long-term strategy for reducing disease burden and antibiotic pressure. Several vaccine candidates are in various stages of development, including live-attenuated strains, subunit vaccines targeting O-antigens, and bioconjugate vaccines. A quadrivalent bioconjugate vaccine targeting S. flexneri 2a, 3a, 6, and S. sonnei has shown promise in clinical trials. The introduction of an effective Shigella vaccine into national immunization programs would substantially reduce the burden of shigellosis and the selective pressure driving antimicrobial resistance.
Public Health Implications
The persistence of S. flexneri as a significant cause of childhood morbidity in Uttar Pradesh reflects broader failures of water, sanitation, and hygiene infrastructure. The fecal-oral transmission route that sustains shigellosis can be interrupted through provision of safe drinking water, adequate sanitation facilities, and promotion of handwashing with soap. However, the scale of investment required to achieve universal coverage in a state of Uttar Pradesh's size and population is enormous, and progress has been slower than necessary.
The Swachh Bharat Mission, India's national sanitation campaign, has made substantial progress in eliminating open defecation and improving toilet access. However, the presence of toilets does not guarantee their use or proper maintenance, and the safe disposal of child feces remains inadequately addressed in many communities. Behavioral change communication to promote consistent toilet use, handwashing, and safe food handling practices is essential to translate infrastructure investments into health gains.
Surveillance for shigellosis in Uttar Pradesh requires strengthening to enable accurate burden estimation, outbreak detection, and monitoring of antimicrobial resistance trends. The Integrated Disease Surveillance Programme provides a framework for reporting, but laboratory confirmation rates remain low and geographical coverage incomplete. Investment in laboratory capacity at district and sub-district levels, training of healthcare personnel in specimen collection and transport, and establishment of reference laboratories for antimicrobial susceptibility testing and molecular characterization are essential.
The antimicrobial resistance crisis demands a coordinated response encompassing human health, animal health, and environmental sectors. The National Action Plan on Antimicrobial Resistance provides a policy framework, but implementation at the state level requires dedicated resources, political commitment, and multisectoral collaboration. Antibiotic stewardship programs in healthcare facilities, regulation of antibiotic sales in the community, and surveillance of antibiotic use and resistance are essential components.
The potential introduction of Shigella vaccines into the national immunization program represents a game-changing opportunity. The development of an affordable, effective vaccine covering the predominant serotypes in India, including S. flexneri 2a, would substantially reduce disease burden and the selective pressure driving antimicrobial resistance. Advocacy for continued investment in vaccine development and evaluation is essential.
Discussion
The landscape of S. flexneri infection in Uttar Pradesh during 2025-2026 reflects both the persistence of historical challenges and the emergence of new threats. The fundamental drivers of transmission—inadequate water, sanitation, and hygiene—remain largely unaddressed despite decades of recognition. The disease burden continues to fall disproportionately upon the most vulnerable: young children, the malnourished, and those living in poverty. And the antimicrobial resistance crisis has reached a point where the availability of effective oral therapy can no longer be assumed.
The shifting serotype epidemiology observed in certain regions of India, with S. sonnei gaining relative prominence as development progresses, has not yet been clearly documented in Uttar Pradesh. This may reflect the state's slower pace of sanitation improvement compared to more economically advanced regions, or simply the limitations of surveillance data. Continued monitoring of serotype distribution is essential, as it has implications for vaccine development and deployment.
The clinical manifestations of S. flexneri infection in Uttar Pradesh appear consistent with patterns described elsewhere in South Asia, with dysentery predominating in older children and severe complications including seizures and hemolytic uremic syndrome occurring primarily in the youngest and most vulnerable. The long-term consequences of repeated infection—growth faltering, impaired cognitive development, and diminished educational attainment—represent a hidden burden that conventional surveillance fails to capture. These sequelae, which perpetuate cycles of poverty and vulnerability, argue for a more holistic approach to shigellosis control that extends beyond acute case management to address the underlying determinants of child health and development.
The antimicrobial resistance situation demands urgent attention. The convergence of resistance to fluoroquinolones, third-generation cephalosporins, and azithromycin in some strains leaves clinicians with essentially no reliable options for oral empirical therapy. The reliance on intravenous ceftriaxone for severe cases, while currently effective against many isolates, is threatened by the emergence of extended-spectrum beta-lactamase production. The development and spread of extensively drug-resistant strains would constitute a public health emergency requiring immediate national and international response.
The path forward requires action on multiple fronts. Investment in water and sanitation infrastructure, while expensive and slow to yield results, remains the fundamental long-term solution. The Swachh Bharat Mission has demonstrated that progress is possible, but sustained commitment and attention to quality and usage are essential. Behavioral change communication to promote handwashing, safe food handling, and appropriate childcare practices can yield substantial benefits even in the absence of infrastructure improvements.
Strengthening surveillance is essential for guiding interventions and monitoring progress. The Integrated Disease Surveillance Programme provides a foundation, but laboratory capacity must be expanded, reporting completeness improved, and data quality enhanced. The integration of antimicrobial resistance surveillance into routine monitoring would enable tracking of resistance trends and early detection of emerging threats.
Antimicrobial stewardship programs, while challenging to implement in resource-limited settings, are essential to preserve the effectiveness of available agents. Education of healthcare providers regarding appropriate antibiotic use, regulation of over-the-counter antibiotic sales, and public awareness campaigns can reduce inappropriate antibiotic consumption and the selective pressure driving resistance.
The development and deployment of effective Shigella vaccines represent the most promising near-term intervention for reducing disease burden and antibiotic pressure. Several vaccine candidates are in advanced stages of development, and the introduction of an effective vaccine into national immunization programs would substantially alter the epidemiological landscape. Advocacy for continued investment in vaccine development, evaluation in relevant populations, and eventual deployment is essential.
The human dimension of shigellosis in Uttar Pradesh must not be forgotten amid the statistics and resistance patterns. Behind each case number lies a child suffering, a family distressed, and a future potentially compromised by the long-term consequences of infection. The mothers who walk miles to reach healthcare facilities, the families who sacrifice scarce resources to pay for treatment, and the children who fall behind in school due to repeated illness deserve our sustained attention and commitment. The control of shigellosis is not merely a technical challenge but a moral imperative rooted in the fundamental right of every child to health and development.
Conclusion
Shigella flexneri remains a significant cause of childhood morbidity in Uttar Pradesh, India, during the period from January 2025 to January 2026. The disease burden falls heaviest upon children under five years of age, with complications including hemolytic uremic syndrome, reactive arthritis, and growth faltering carrying substantial long-term consequences. Antimicrobial resistance has reached crisis proportions, with multidrug resistance now the norm and increasing resistance to fluoroquinolones, third-generation cephalosporins, and azithromycin threatening to exhaust available treatment options. The persistence of shigellosis reflects broader failures of water, sanitation, and hygiene infrastructure that require sustained investment and multisectoral collaboration to address. Strengthening surveillance, implementing antimicrobial stewardship programs, accelerating vaccine development, and investing in water and sanitation infrastructure are essential to controlling this persistent public health threat. The children of Uttar Pradesh, and of all regions where shigellosis persists, deserve nothing less than our complete and urgent commitment to eliminating this preventable disease.
References
Taneja N, Mewara A. Shigellosis: epidemiology in India. Indian J Med Res. 2016;143(5):565-576.
Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. Shigellosis. Lancet. 2018;391(10122):801-812.
Global Burden of Disease Study 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1211-1228.
Livio S, Strockbine NA, Panchalingam S, et al. Shigella isolates from the Global Enteric Multicenter Study inform vaccine development. Clin Infect Dis. 2014;59(7):933-941.
Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.
World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. Geneva: WHO; 2005.
World Health Organization. The treatment of diarrhoea: a manual for physicians and other senior health workers. 4th ed. Geneva: WHO; 2005.
Taneja N, Lyngdoh V, Vermani A, Mohan B, Rao P, Singh M, Sharma M. Re-emergence of multi-drug resistant Shigella dysenteriae with added resistance to ciprofloxacin in north India & their plasmid profiles. Indian J Med Res. 2005;122(4):348-354.
Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigellae in India. J Clin Microbiol. 2007;45(2):678-679.
Pazhani GP, Ramamurthy T, Mitra U, Bhattacharya SK, Niyogi SK. Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India. Epidemiol Infect. 2005;133(6):1089-1095.
Bhattacharya D, Bhattacharya H, Thamizhmani R, Sayi DS, Reesu R, Anwesh M, et al. Shigellosis in Bay of Bengal Islands, India: clinical and seasonal patterns, surveillance of antibiotic susceptibility patterns, and molecular characterization of multidrug-resistant Shigella strains isolated during a 6-year period from 2006 to 2011. Eur J Clin Microbiol Infect Dis. 2014;33(2):157-170.
Jain PA, Kulkarni RD, Dutta S, Ganavali AS, Kalabhavi AS, Shetty PC, et al. Prevalence and antimicrobial profile of Shigella isolates in a tertiary care hospital of North Karnataka: a 12-year study. Indian J Med Microbiol. 2020;38(1):101-108.
Prasad KN, Xess AB. Prevalence and antimicrobial susceptibility pattern of Shigella in a tertiary care hospital of North India. Indian J Med Microbiol. 2013;31(3):246-249.
Sur D, Ramamurthy T, Deen J, Bhattacharya SK. Shigellosis: challenges & management issues. Indian J Med Res. 2004;120(5):454-462.
Ramamurthy T, Ghosh A, Panchal N, Haldar B, Dutta S, Itoh K, et al. Current status of the non-O1, non-O139 serogroup of Vibrio cholerae infections in Kolkata, India. J Infect Dis. 2009;200(11):1792-1794.
World Health Organization. WHO model list of essential medicines for children. 8th ed. Geneva: WHO; 2021.
Centers for Disease Control and Prevention. Shigella – Shigellosis. Atlanta: CDC; 2024.
Kotloff KL, Nasrin D, Blackwelder WC, et al. The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: a 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS). Lancet Glob Health. 2019;7(5):e568-e584.
Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Immunity and immunological memory following smallpox vaccination. Immunol Rev. 2011;239(1):320-337.
Mani S, Wierzba T, Walker RI. Status of vaccine research and development for Shigella. Vaccine. 2016;34(26):2887-2894.